[go: up one dir, main page]

CO5190673A1 - Nueva composicion y uso liberacion modificada - Google Patents

Nueva composicion y uso liberacion modificada

Info

Publication number
CO5190673A1
CO5190673A1 CO99070989A CO99070989A CO5190673A1 CO 5190673 A1 CO5190673 A1 CO 5190673A1 CO 99070989 A CO99070989 A CO 99070989A CO 99070989 A CO99070989 A CO 99070989A CO 5190673 A1 CO5190673 A1 CO 5190673A1
Authority
CO
Colombia
Prior art keywords
modified release
new composition
use modified
composition
agent
Prior art date
Application number
CO99070989A
Other languages
English (en)
Inventor
Robert Glinecke
Susan Marie Milosovich
William Muldoon
Vicenzo Re
Joseph Sauer
Janet Louise Skinner
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of CO5190673A1 publication Critical patent/CO5190673A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica que comprende un agente anti-hiperglucemiante y un vehículo farmacéuticamente aceptable para el mismo, dicha composición dispuesta para proporcionar una liberación sostenida de dicho agente.Una composición según la reivindicación 1, en la cual dicho vehículo esta dispuesto para proporcionar también una liberación sostenida del agente anti-hiperglucemiante.
CO99070989A 1998-11-12 1999-11-11 Nueva composicion y uso liberacion modificada CO5190673A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
CO5190673A1 true CO5190673A1 (es) 2002-08-29

Family

ID=26314667

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99070989A CO5190673A1 (es) 1998-11-12 1999-11-11 Nueva composicion y uso liberacion modificada

Country Status (39)

Country Link
EP (3) EP1815855A1 (es)
JP (1) JP2002529505A (es)
KR (2) KR20060097140A (es)
CN (1) CN1289081C (es)
AP (2) AP2008004490A0 (es)
AR (2) AR023700A1 (es)
AT (1) ATE382352T1 (es)
AU (1) AU768578B2 (es)
BG (2) BG65444B1 (es)
BR (1) BR9915215A (es)
CA (1) CA2350659C (es)
CO (1) CO5190673A1 (es)
CY (1) CY1107909T1 (es)
CZ (1) CZ20011628A3 (es)
DE (1) DE69937898T2 (es)
DK (1) DK1128827T3 (es)
DZ (1) DZ2937A1 (es)
EA (3) EA007608B1 (es)
EG (2) EG22344A (es)
ES (1) ES2299269T3 (es)
HK (1) HK1040909B (es)
HR (2) HRP20010342B1 (es)
HU (1) HUP0104307A3 (es)
ID (1) ID29344A (es)
IL (2) IL143003A0 (es)
MY (1) MY135973A (es)
NO (1) NO20012351L (es)
NZ (2) NZ511611A (es)
OA (1) OA11676A (es)
PE (1) PE20001428A1 (es)
PL (1) PL198717B1 (es)
PT (1) PT1128827E (es)
RS (1) RS50208B (es)
SI (1) SI1128827T1 (es)
SK (1) SK286937B6 (es)
TR (2) TR200101337T2 (es)
TW (2) TWI257305B (es)
UY (2) UY25798A1 (es)
WO (1) WO2000028990A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
EP1244468A2 (en) * 2000-01-07 2002-10-02 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
ES2298236T3 (es) * 2001-01-31 2008-05-16 Evonik Rohm Gmbh Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
ES2259736T3 (es) * 2001-12-21 2006-10-16 Smithkline Beecham Corporation Regimen de dosificacion para activadores de ppar-gamma-.
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
WO2004006921A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
WO2004062577A2 (en) 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
CA2878866C (en) * 2011-07-14 2021-02-23 Able Cerebral, Llc A composition, device and method for delayed and sustained release of brain energy molecules
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0533933A4 (en) 1990-07-03 1993-05-05 Yamanouchi Pharmaceutical Co. Ltd. Bisheterocyclic compound
AU645112B2 (en) 1990-08-23 1994-01-06 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
EP0648212B1 (en) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2001521551A (ja) * 1997-03-24 2001-11-06 ガルデルマ リサーチ アンド デヴェロップメント エス エヌ セ インスリン非依存性糖尿病の治療のためのレチノイド関連分子

Also Published As

Publication number Publication date
NO20012351L (no) 2001-07-04
HUP0104307A2 (hu) 2002-07-29
MY135973A (en) 2008-07-31
AP1901A (en) 2008-10-24
CA2350659A1 (en) 2000-05-25
BG109893A (bg) 2008-11-28
EP1917962A1 (en) 2008-05-07
PL198717B1 (pl) 2008-07-31
BR9915215A (pt) 2001-07-31
KR100732599B1 (ko) 2007-06-27
CA2350659C (en) 2009-06-09
CN1333683A (zh) 2002-01-30
SK6432001A3 (en) 2001-12-03
EA200100540A1 (ru) 2001-10-22
EA007608B1 (ru) 2006-12-29
KR20060097140A (ko) 2006-09-13
UY25800A1 (es) 2000-08-21
NZ526440A (en) 2005-01-28
AU1272900A (en) 2000-06-05
RS50208B (sr) 2009-07-15
ID29344A (id) 2001-08-23
WO2000028990A1 (en) 2000-05-25
JP2002529505A (ja) 2002-09-10
CY1107909T1 (el) 2013-09-04
AR023700A1 (es) 2002-09-04
CN1289081C (zh) 2006-12-13
KR20010073229A (ko) 2001-07-31
EP1815855A1 (en) 2007-08-08
PE20001428A1 (es) 2001-02-08
ATE382352T1 (de) 2008-01-15
SI1128827T1 (sl) 2008-06-30
PT1128827E (pt) 2008-03-10
EA200702648A1 (ru) 2008-10-30
AR023699A1 (es) 2002-09-04
AU768578B2 (en) 2003-12-18
EG22344A (en) 2002-12-31
PL348153A1 (en) 2002-05-06
HUP0104307A3 (en) 2003-12-29
IL143003A0 (en) 2002-04-21
TWI246920B (en) 2006-01-11
TWI257305B (en) 2006-07-01
OA11676A (en) 2005-01-12
BG105570A (en) 2002-02-28
HRP20080117A2 (en) 2008-10-31
DK1128827T3 (da) 2008-04-28
EP1128827B1 (en) 2008-01-02
IL183972A0 (en) 2007-10-31
DE69937898T2 (de) 2009-01-02
TR200503846T2 (tr) 2007-01-22
EG24463A (en) 2009-07-16
HRP20010342A2 (en) 2002-06-30
NO20012351D0 (no) 2001-05-11
HRP20010342B1 (en) 2008-04-30
BG65444B1 (bg) 2008-08-29
HK1040909A1 (en) 2002-06-28
NZ511611A (en) 2003-10-31
HK1040909B (zh) 2008-08-01
CZ20011628A3 (cs) 2001-12-12
YU36401A (sh) 2004-05-12
DE69937898D1 (de) 2008-02-14
UY25798A1 (es) 2000-12-29
EA200601144A1 (ru) 2007-02-27
EP1128827A1 (en) 2001-09-05
TR200101337T2 (tr) 2001-11-21
AP2008004490A0 (en) 2008-06-30
DZ2937A1 (fr) 2004-03-15
SK286937B6 (sk) 2009-07-06
ES2299269T3 (es) 2008-05-16
TW200505436A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
CO5190673A1 (es) Nueva composicion y uso liberacion modificada
AR003908A1 (es) Tableta de liberacion controlada
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
AR002355A1 (es) Composiciones y metodos para administracion local de agentes farmaceuticamente activos.
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
AR002932A1 (es) Solucion acuosa de interferon
MY124695A (en) Novel composition and use.
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ATE383165T1 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung, die wasserunlösliche komplexverbindungen enthalten
ES2195970T3 (es) L-ribavirina y usos de la misma.
KR870005637A (ko) 약물 데포
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
AR017222A1 (es) Procedimiento de utilizacion de un agente que inhibe el desarrollo de p.ovale, en la preparacion de medicamentos
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
ATE262911T1 (de) Pharmazeutische präparate, insbesondere ovula, die viele verschiedene aktive bestandteile enthalten
AR003889A1 (es) Una composición depilatoria y el uso de agentes tixotrópico.
CO5231137A1 (es) Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes
ES2166900T3 (es) Derivados de ara-c.
BR9805042A (pt) Composto e composição.
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR023781A1 (es) Formulaciones farmaceuticas
MX9306296A (es) Composiciones anestesicas y su uso.

Legal Events

Date Code Title Description
FC Application refused